{
  "meta": {
    "title": "Cancer_Biology_-_2_Cell_Cycle_Dna_Repair_Cell_Death",
    "url": "https://brainandscalpel.vercel.app/cancer-biology-2-cell-cycle-dna-repair-cell-death-d1823f4d.html",
    "scrapedAt": "2025-11-29T18:24:57.126Z"
  },
  "questions": [
    {
      "id": 19757,
      "choices": [
        {
          "id": 78989,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDKN2A (p16INK4A) mutation </span></span></p>"
        },
        {
          "id": 78990,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CDKN1B (p27) mutation</span></span></p>"
        },
        {
          "id": 78991,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CCND1 amplification</span></span></p>"
        },
        {
          "id": 78992,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TP53 mutation</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with mantle cell lymphoma (MCL). Which of the following genetic alterations is MOST likely associated with this malignancy?</span></span></p>",
      "unique_key": "Q4299528",
      "question_audio": null,
      "question_video": null,
      "map_id": 19590,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) CCND1 amplification</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows that CCND1 amplification is associated with MCL. CCND1 encodes Cyclin D1, a protein that promotes the G1/S phase transition in the cell cycle. Amplification of this gene leads to overexpression of Cyclin D1 and uncontrolled cell proliferation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CDKN2A (p16INK4A) mutation:</span></strong><span style=\"font-size:12.0pt\"> While CDKN2A mutations can be seen in various cancers, they are more commonly associated with melanoma and other solid tumors. In mantle cell lymphoma, CDKN2A deletions are associated with poor prognosis but are not the primary driver of the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CDKN1B (p27) mutation:</span></strong><span style=\"font-size:12.0pt\"> Mutations in CDKN1B are associated with MEN4 syndrome (multiple endocrine neoplasia type 4) and can be seen in other cancers, but not typically in mantle cell lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. TP53 mutation:</span></strong><span style=\"font-size:12.0pt\"> TP53 is a tumor suppressor gene, and mutations are found in various cancers. While TP53 mutations can occur in MCL and are associated with a worse prognosis, they are not the primary genetic alteration driving the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CCND1 amplification is a hallmark of mantle cell lymphoma.</span></span></p>",
      "correct_choice_id": 78991,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19758,
      "choices": [
        {
          "id": 78993,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition</span></span></p>"
        },
        {
          "id": 78994,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of topoisomerase II in the S phase</span></span></p>"
        },
        {
          "id": 78995,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of microtubule formation in the M phase</span></span></p>"
        },
        {
          "id": 78996,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of DNA repair enzymes in the G2 phase</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman is diagnosed with breast cancer and is referred to an oncologist for treatment. The tumor is found to be estrogen receptor-positive and HER2-negative. The oncologist discusses the use of a targeted therapy that specifically interferes with the cell cycle of cancer cells, thereby inhibiting their proliferation. The medication targets a specific phase of the cell cycle, leading to cell cycle arrest and eventual apoptosis of the cancer cells. Which of the following best describes the mechanism of action of the medication likely prescribed to this patient?</span></span></p>",
      "unique_key": "Q7255748",
      "question_audio": null,
      "question_video": null,
      "map_id": 19591,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>A) Inhibition of cyclin-dependent kinases (CDKs) in the G1/S phase transition</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In estrogen receptor-positive, HER2-negative breast cancer, a common targeted therapy is the use of CDK4/6 inhibitors, such as palbociclib, ribociclib, or abemaciclib. These medications work by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for the progression of the cell cycle from the G1 phase to the S phase. By inhibiting these kinases, the medication induces cell cycle arrest at the G1/S transition, preventing cancer cells from replicating their DNA and dividing. This leads to a reduction in tumor growth and can enhance the effectiveness of other therapies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Activation of topoisomerase II in the S phase</span></strong><span style=\"font-size:12.0pt\">: Topoisomerase II inhibitors, such as etoposide, work by interfering with the action of topoisomerase II, an enzyme involved in DNA replication and cell division during the S phase. This mechanism is not specific to CDK inhibitors used in breast cancer treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibition of microtubule formation in the M phase</span></strong><span style=\"font-size:12.0pt\">: Microtubule inhibitors, such as taxanes (e.g., paclitaxel), target the M phase of the cell cycle by preventing the formation of microtubules, which are essential for chromosome separation during cell division. This mechanism is different from that of CDK inhibitors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Activation of DNA repair enzymes in the G2 phase</span></strong><span style=\"font-size:12.0pt\">: This option is not a common mechanism for targeted therapy in breast cancer. Drugs that target DNA repair pathways typically work by inhibiting, not activating, DNA repair enzymes to prevent cancer cells from repairing DNA damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin-dependent kinase (CDK) inhibitors, such as palbociclib, ribociclib, and abemaciclib, are used in the treatment of estrogen receptor-positive, HER2-negative breast cancer. They work by inhibiting CDK4/6, leading to cell cycle arrest at the G1/S transition and preventing cancer cell proliferation.</span></span></p>",
      "correct_choice_id": 78993,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19759,
      "choices": [
        {
          "id": 78997,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin A</span></span></p>"
        },
        {
          "id": 78998,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin-dependent kinase 2 (CDK2)</span></span></p>"
        },
        {
          "id": 78999,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">p21</span></span></p>"
        },
        {
          "id": 79000,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin E</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a negative regulator that prevents the progression of cells from the G1 phase to the S phase in the cell cycle?</span></span></p>",
      "unique_key": "Q4953150",
      "question_audio": null,
      "question_video": null,
      "map_id": 19592,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\">. <strong>C) p21</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">p21 is a negative regulator of the cell cycle that prevents the progression of cells from the G1 phase to the S phase. It is a cyclin-dependent kinase (CDK) inhibitor that binds to and inhibits the activity of cyclin-CDK complexes, such as cyclin E-CDK2 and cyclin A-CDK2, which are required for the transition from the G1 phase to the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cyclin A:</span></strong><span style=\"font-size:12.0pt\"> Is a positive regulator of the cell cycle that activates CDK2, promoting progression through the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cyclin-dependent kinase 2 (CDK2):</span></strong><span style=\"font-size:12.0pt\"> Is a positive regulator that, when activated by cyclins such as cyclin E and cyclin A, helps drive the cell cycle from the G1 phase to the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cyclin E:</span></strong><span style=\"font-size:12.0pt\"> Is a positive regulator of the cell cycle that activates CDK2, promoting the transition from the G1 phase to the S phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">p21 is a negative regulator of the cell cycle that inhibits the activity of cyclin-CDK complexes, preventing the progression of cells from the G1 phase to the S phase. </span></span></p>",
      "correct_choice_id": 78999,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19760,
      "choices": [
        {
          "id": 79001,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1 mutation </span></span></p>"
        },
        {
          "id": 79002,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MUTYH mutation </span></span></p>"
        },
        {
          "id": 79003,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MSH2 mutation </span></span></p>"
        },
        {
          "id": 79004,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ATM mutation</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman presents with a family history of early-onset colon cancer and multiple family members affected by various types of cancer. Which of the following genetic mutations is MOST likely responsible for her increased cancer risk?</span></span></p>",
      "unique_key": "Q5691803",
      "question_audio": null,
      "question_video": null,
      "map_id": 19593,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) MSH2 mutation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation suggests Lynch syndrome (Hereditary Non-Polyposis Colorectal Cancer or HNPCC), which is caused by germline mutations in mismatch repair (MMR) genes, including MSH2. BRCA1 is associated with breast and ovarian cancer, MUTYH with a specific type of colorectal cancer, and ATM with ataxia-telangiectasia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. BRCA1 mutation:</span></strong><span style=\"font-size:12.0pt\"> BRCA1 mutations are primarily associated with increased risks of breast and ovarian cancers. While they can increase the risk of other cancers, the patient&#39;s family history of colon cancer makes this less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. MUTYH mutation:</span></strong><span style=\"font-size:12.0pt\"> MUTYH mutations are associated with MUTYH-associated polyposis (MAP), a hereditary condition that increases the risk of colorectal cancer. However, MAP usually presents with multiple polyps, and the patient&#39;s family history doesn&#39;t necessarily fit this pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ATM mutation:</span></strong><span style=\"font-size:12.0pt\"> ATM mutations are associated with ataxia-telangiectasia, a rare neurodegenerative disorder characterized by ataxia, telangiectasias (small dilated blood vessels), and immune deficiencies. While individuals with ataxia-telangiectasia have an increased risk of certain cancers, the presentation in this question doesn&#39;t match the typical features of this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MSH2 mutations are associated with Lynch syndrome, a hereditary cancer syndrome that significantly increases the risk of various cancers, including colorectal, endometrial, and ovarian cancer.</span></span></span></p>",
      "correct_choice_id": 79003,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19761,
      "choices": [
        {
          "id": 79005,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-homologous end joining (NHEJ)</span></span></p>"
        },
        {
          "id": 79006,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Base excision repair (BER)</span></span></p>"
        },
        {
          "id": 79007,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homologous recombination (HR)</span></span></p>"
        },
        {
          "id": 79008,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Single-strand break repair</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman presents to your clinic with a newly discovered breast mass. Her family history is significant for multiple cases of breast and ovarian cancer, including her mother and sister. Genetic testing reveals a germline BRCA1 mutation. Which of the following DNA repair pathways is MOST likely deficient in this patient, contributing to her increased cancer risk?</span></span></p>",
      "unique_key": "Q7115506",
      "question_audio": null,
      "question_video": null,
      "map_id": 19594,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Homologous recombination (HR)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 is a tumor suppressor gene that plays a crucial role in homologous recombination (HR), a DNA repair mechanism responsible for repairing double-stranded DNA breaks. A germline mutation in BRCA1 disrupts the HR pathway, leading to genomic instability and increasing the risk of developing breast and ovarian cancers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Non-homologous end joining (NHEJ):</span></strong><span style=\"font-size:12.0pt\"> While important for DNA repair, NHEJ is not the primary pathway affected by BRCA1 mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Base excision repair (BER):</span></strong><span style=\"font-size:12.0pt\"> BER is primarily responsible for repairing single-base DNA damage and is not directly affected by BRCA1 mutations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Single-strand break repair:</span></strong><span style=\"font-size:12.0pt\"> This is a broader term encompassing several pathways, including BER and PARP. While PARP inhibitors are used in BRCA-mutant cancers, the primary defect lies in HR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRCA1 mutations lead to a deficiency in homologous recombination (HR), a critical DNA repair mechanism. This defect contributes to genomic instability and significantly increases the risk of breast and ovarian cancers in affected individuals.</span></span></span></p>",
      "correct_choice_id": 79007,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19762,
      "choices": [
        {
          "id": 79009,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Base excision repair (BER) </span></span></p>"
        },
        {
          "id": 79010,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nucleotide excision repair (NER)</span></span></p>"
        },
        {
          "id": 79011,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homologous recombination (HR)</span></span></p>"
        },
        {
          "id": 79012,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-homologous end joining (NHEJ)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child is brought to your clinic by their parents, who are concerned about their child&#39;s extreme sensitivity to sunlight. The child easily sunburns and has developed multiple freckles and skin lesions after minimal sun exposure. On examination, you notice dry skin and patches of hypopigmentation. You suspect an underlying genetic disorder affecting DNA repair mechanisms. Which of the following DNA repair pathways is MOST likely deficient in this child?</span></span></p>",
      "unique_key": "Q6481675",
      "question_audio": null,
      "question_video": null,
      "map_id": 19595,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Nucleotide excision repair (NER)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The child&#39;s clinical presentation of photosensitivity, skin lesions, and pigmentary changes is highly suggestive of xeroderma pigmentosum (XP). XP is a rare autosomal recessive disorder characterized by defective nucleotide excision repair (NER). NER is the primary mechanism for repairing DNA damage caused by ultraviolet (UV) radiation from the sun.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Base excision repair (BER):</span></strong><span style=\"font-size:12.0pt\"> BER primarily repairs damage to single bases in DNA, often caused by oxidation or alkylation. While important, it&#39;s not the primary pathway for repairing the type of damage caused by UV radiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Homologous recombination (HR):</span></strong><span style=\"font-size:12.0pt\"> HR is a complex process used to repair double-stranded DNA breaks. While critical for genome stability, it&#39;s not the main mechanism for repairing UV-induced DNA damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Non-homologous end joining (NHEJ):</span></strong><span style=\"font-size:12.0pt\"> Similar to HR, NHEJ repairs double-stranded breaks but does not play a major role in repairing UV-induced damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The inability to repair UV-induced DNA damage in XP leads to a significantly increased risk of skin cancer at a young age, as well as other complications like ocular problems and neurological abnormalities. Early diagnosis and strict sun protection measures are crucial for managing XP.</span></span></span></p>",
      "correct_choice_id": 79010,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53460,
      "choices": [
        {
          "id": 213321,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apoptosis </span></span></p>"
        },
        {
          "id": 213322,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necroptosis </span></span></p>"
        },
        {
          "id": 213323,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pyroptosis </span></span></p>"
        },
        {
          "id": 213324,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necrosis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A researcher is investigating a new drug that inhibits the formation of the inflammasome complex. Which of the following types of cell death would be MOST directly affected by this drug?</span></span></p>",
      "unique_key": "Q1372805",
      "question_audio": null,
      "question_video": null,
      "map_id": 25264,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Pyroptosis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The inflammasome is a key component of the pyroptosis pathway, responsible for activating caspase-1 and ultimately leading to inflammatory cell death. Inhibiting the inflammasome would therefore block pyroptosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Apoptosis:</span></strong><span style=\"font-size:12.0pt\"> Apoptosis is a programmed cell death pathway, but it is not directly dependent on the inflammasome. It involves a different set of caspases (caspase-3, -6, -7) and is not typically associated with the same inflammatory response as pyroptosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Necroptosis:</span></strong><span style=\"font-size:12.0pt\"> Necroptosis is another form of programmed cell death, but it is regulated by the RIPK1-RIPK3-MLKL pathway, not the inflammasome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Necrosis:</span></strong><span style=\"font-size:12.0pt\"> Necrosis is an unregulated form of cell death that is typically caused by injury or trauma. It is not a programmed process and is not mediated by the inflammasome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The inflammasome is a multiprotein complex that plays a central role in pyroptosis. It senses danger signals and activates caspase-1, leading to the production of pro-inflammatory cytokines and ultimately cell death with membrane rupture. By inhibiting the inflammasome, the drug would directly block the pyroptotic pathway.</span></span></span></p>",
      "correct_choice_id": 213323,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53461,
      "choices": [
        {
          "id": 213325,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apoptosis </span></span></p>"
        },
        {
          "id": 213326,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necroptosis </span></span></p>"
        },
        {
          "id": 213327,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pyroptosis </span></span></p>"
        },
        {
          "id": 213328,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Necrosis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A biopsy of a patient&#39;s liver reveals hepatocytes with extensive swelling, loss of plasma membrane integrity, and leakage of cellular contents into the surrounding tissue. Which of the following types of cell death is MOST likely occurring in these cells?</span></span></p>",
      "unique_key": "Q2549676",
      "question_audio": null,
      "question_video": null,
      "map_id": 25265,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Necrosis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The described morphological changes are characteristic of necrosis, an uncontrolled form of cell death that results from cellular injury. Apoptosis, necroptosis, and pyroptosis are forms of programmed cell death with distinct features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><span style=\"font-size:12.0pt\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Apoptosis:</span></strong><span style=\"font-size:12.0pt\"> Apoptosis is a programmed cell death that involves cell shrinkage, nuclear condensation, and fragmentation into apoptotic bodies, without leakage of cellular contents.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Necroptosis:</span></strong><span style=\"font-size:12.0pt\"> Necroptosis is a regulated form of cell death that shares some features with necrosis, such as cell swelling and membrane rupture. However, it is initiated by specific signaling pathways and does not typically occur in the liver in response to injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pyroptosis:</span></strong><span style=\"font-size:12.0pt\"> Pyroptosis is an inflammatory form of programmed cell death that involves the formation of pores in the cell membrane, but it is primarily associated with immune responses to infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Necrosis is an unregulated cell death process characterized by cell swelling, membrane rupture, and leakage of cellular contents.</span></span></span></p>",
      "correct_choice_id": 213328,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53462,
      "choices": [
        {
          "id": 213329,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Overexpression of BCL-2 </span></span></p>"
        },
        {
          "id": 213330,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loss of p53 function </span></span></p>"
        },
        {
          "id": 213331,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of RAS </span></span></p>"
        },
        {
          "id": 213332,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amplification of MYC</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with follicular lymphoma (FL) is found to have a t(14;18) translocation. Which of the following is the MOST likely consequence of this translocation?</span></span></p>",
      "unique_key": "Q3814609",
      "question_audio": null,
      "question_video": null,
      "map_id": 25266,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Overexpression of BCL-2</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(14;18) translocation juxtaposes the BCL-2 gene with the immunoglobulin heavy chain (IgH) locus, leading to overexpression of BCL-2, an anti-apoptotic protein.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Loss of p53 function:</span></strong><span style=\"font-size:12.0pt\"> While TP53 mutations (leading to loss of p53 function) are common in many cancers, they are not the primary driver of follicular lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Activation of RAS:</span></strong><span style=\"font-size:12.0pt\"> RAS mutations are associated with various cancers, but they are not the hallmark of follicular lymphoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Amplification of MYC:</span></strong><span style=\"font-size:12.0pt\"> MYC amplification is more commonly associated with Burkitt lymphoma and other aggressive lymphomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The t(14;18) translocation is a hallmark of follicular lymphoma and contributes to its pathogenesis by inhibiting apoptosis.</span></span></span></p>",
      "correct_choice_id": 213329,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}